# Jardiance (Empagliflozin) Drug Interactions

## Drug Overview
- **Generic Name:** Empagliflozin
- **Brand Name:** Jardiance
- **Drug Class:** SGLT2 Inhibitor (Sodium-Glucose Cotransporter 2 Inhibitor)
- **Primary Uses:** 
  - Type 2 Diabetes Mellitus
  - Heart Failure (with reduced or preserved ejection fraction)
  - Chronic Kidney Disease (CKD) with risk of progression
- **Mechanism:** Inhibits SGLT2 in proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion; also promotes natriuresis and reduces preload
- **FDA Approval:** 2014
- **Dosage Forms:** 10 mg, 25 mg tablets

---

## Major Drug-Drug Interactions (Severity: HIGH - Significant Clinical Concern)

### 1. Other SGLT2 Inhibitors
- **Interacting Drugs:** Dapagliflozin (Farxiga), Canagliflozin (Invokana), Ertugliflozin (Steglatro), Bexagliflozin
- **Interaction Type:** Pharmacodynamic duplication
- **Mechanism:** Same mechanism of action; additive effects
- **Clinical Effect:** 
  - Excessive glucose excretion
  - Increased risk of dehydration
  - Increased ketoacidosis risk
  - No additional benefit expected
- **Management:** Do NOT combine SGLT2 inhibitors; use only one agent from this class
- **Source:** FDA Prescribing Information; Drugs.com

### 2. Insulin (Hypoglycemia Risk)
- **Interacting Drugs:** All insulins (glargine, lispro, aspart, detemir, degludec, regular, NPH)
- **Interaction Type:** Additive glucose-lowering effect
- **Mechanism:** Both lower blood glucose through different mechanisms
- **Clinical Effect:** Increased risk of hypoglycemia
- **Management:** 
  - Consider LOWER insulin dose when initiating Jardiance
  - Monitor blood glucose closely
  - Patient education on hypoglycemia recognition
- **Source:** FDA Prescribing Information; Medscape Drug Interactions

### 3. Insulin Secretagogues (Hypoglycemia Risk)
- **Interacting Drugs:** 
  - Sulfonylureas: Glipizide, Glimepiride, Glyburide
  - Meglitinides: Repaglinide, Nateglinide
- **Interaction Type:** Additive hypoglycemic effect
- **Mechanism:** Sulfonylureas/meglitinides stimulate insulin release; combination increases hypoglycemia
- **Clinical Effect:** Significant hypoglycemia risk
- **Management:** 
  - Consider LOWER dose of sulfonylurea when adding Jardiance
  - Frequent glucose monitoring
  - Patient education
- **Source:** FDA Prescribing Information; GoodRx Clinical Review

---

## Moderate Drug-Drug Interactions (Severity: MODERATE - Monitor Closely)

### Diuretics (Volume Depletion Risk)

#### Loop Diuretics
- **Interacting Drugs:** Furosemide (Lasix), Bumetanide, Torsemide, Ethacrynic acid
- **Interaction Type:** Additive diuretic/volume-depleting effect
- **Mechanism:** 
  - Jardiance causes osmotic diuresis via glucose excretion
  - Loop diuretics cause natriuresis
  - Combined effect enhances volume depletion
- **Clinical Effect:**
  - Hypotension (including orthostatic hypotension)
  - Dehydration
  - Acute kidney injury (especially in elderly)
  - Electrolyte disturbances
- **Management:**
  - Assess volume status before starting Jardiance
  - May need to reduce diuretic dose
  - Monitor blood pressure and renal function
  - Encourage adequate hydration
- **Source:** FDA Prescribing Information; Medscape Drug Interactions

#### Thiazide Diuretics
- **Interacting Drugs:** Hydrochlorothiazide, Chlorthalidone, Indapamide, Metolazone
- **Interaction Type:** Additive volume depletion
- **Clinical Effect:** Hypotension, dehydration, AKI
- **Management:** Same as loop diuretics
- **Source:** FDA Prescribing Information; Drugs.com

#### Potassium-Sparing Diuretics
- **Interacting Drugs:** Spironolactone, Eplerenone, Amiloride, Triamterene
- **Interaction Type:** Additive diuretic effect
- **Clinical Effect:** Enhanced volume depletion; variable potassium effects
- **Management:** Monitor volume status, blood pressure, electrolytes
- **Source:** Medscape Drug Interactions

### Lithium
- **Interacting Drug:** Lithium (Lithobid)
- **Interaction Type:** Altered lithium excretion
- **Mechanism:** Jardiance-induced diuresis may affect lithium levels
- **Clinical Effect:** 
  - Potential for increased lithium levels if dehydrated
  - Risk of lithium toxicity
- **Management:** 
  - Monitor lithium levels more frequently
  - Ensure adequate hydration
  - Watch for signs of lithium toxicity
- **Source:** WebMD Drug Interactions; GoodRx Clinical Review

### Other Antidiabetic Agents (Additive Effects)

#### Metformin
- **Interacting Drug:** Metformin
- **Interaction Type:** Additive glucose lowering
- **Clinical Effect:** Enhanced glycemic control (desired effect); low hypoglycemia risk with this combination
- **Management:** Commonly and safely used together; monitor glucose
- **Source:** FDA Prescribing Information (Synjardy); Clinical studies

#### GLP-1 Receptor Agonists
- **Interacting Drugs:** Semaglutide (Ozempic), Dulaglutide (Trulicity), Liraglutide (Victoza)
- **Interaction Type:** Additive glucose lowering
- **Clinical Effect:** Enhanced efficacy; low hypoglycemia risk when not combined with insulin/sulfonylureas
- **Management:** Often used together; monitor glucose and for GI side effects
- **Source:** Clinical practice guidelines; Drugs.com

#### DPP-4 Inhibitors
- **Interacting Drugs:** Sitagliptin (Januvia), Saxagliptin, Linagliptin, Alogliptin
- **Interaction Type:** Additive glucose lowering
- **Clinical Effect:** Enhanced glycemic control
- **Management:** Safe combination; linagliptin + empagliflozin available as Glyxambi
- **Source:** FDA Prescribing Information

#### Pioglitazone
- **Interacting Drug:** Pioglitazone (Actos)
- **Interaction Type:** Additive glucose lowering
- **Clinical Effect:** Enhanced efficacy; potential for fluid retention with TZD
- **Management:** Monitor for signs of heart failure; Jardiance may partially offset TZD fluid retention
- **Source:** Clinical literature; Drugs.com

### ACE Inhibitors and ARBs
- **Interacting Drugs:** 
  - ACE-I: Lisinopril, Enalapril, Ramipril, Benazepril
  - ARBs: Losartan, Valsartan, Irbesartan, Candesartan
- **Interaction Type:** Additive hypotensive and renal effects
- **Clinical Effect:** 
  - Enhanced blood pressure lowering
  - Potential for hypotension
  - Initial eGFR decrease common (usually stabilizes)
- **Management:** Monitor blood pressure and renal function, especially at initiation
- **Source:** Clinical experience; Drugs.com

---

## Drug-Food and Drug-Supplement Interactions

### Alcohol
- **Severity:** Moderate
- **Mechanism:** Both Jardiance and alcohol can affect hydration status; alcohol affects glucose levels
- **Clinical Effect:** 
  - May worsen dehydration risk
  - Unpredictable glucose effects
- **Management:** Moderate alcohol consumption; ensure adequate hydration
- **Source:** Drugs.com Food Interactions

### Supplements That May Affect Blood Glucose

#### Vitamin B3 (Niacin)
- **Interaction Type:** May impair glucose tolerance
- **Clinical Effect:** Potential decrease in Jardiance efficacy
- **Management:** Monitor blood glucose
- **Source:** GoodRx Clinical Review

#### Ginseng
- **Interaction Type:** May lower blood sugar
- **Clinical Effect:** Potential additive hypoglycemia (mild)
- **Management:** Monitor blood glucose
- **Source:** GoodRx Clinical Review

#### Ginkgo Biloba
- **Interaction Type:** May affect glucose metabolism
- **Clinical Effect:** Variable glucose effects
- **Management:** Monitor blood glucose
- **Source:** GoodRx Clinical Review

#### Chromium
- **Interaction Type:** May lower blood sugar
- **Clinical Effect:** Potential additive glucose lowering
- **Management:** Monitor glucose if using chromium supplements
- **Source:** GoodRx Clinical Review

### Foods to Consider

#### High-Sugar Foods
- **Effect:** May counteract Jardiance benefits
- **Management:** Follow diabetes diet recommendations
- **Source:** Clinical practice

#### Caffeine
- **Effect:** May worsen some Jardiance side effects (urination frequency)
- **Management:** Moderate caffeine intake
- **Source:** GoodRx Clinical Review

---

## Drug-Disease Interactions

### 1. Renal Dysfunction (Major)
- **Condition:** Impaired kidney function
- **Interaction:** 
  - Glucose-lowering efficacy decreases with declining eGFR
  - Increased risk of volume depletion-related adverse effects
  - Risk of acute kidney injury in susceptible patients
- **Guidelines:**
  - Diabetes: Not recommended to initiate if eGFR <30 mL/min/1.73m²
  - Heart Failure/CKD: Can use with lower eGFR (per indication-specific labeling)
  - Dialysis: Contraindicated
- **Management:** 
  - Assess renal function before and during therapy
  - Monitor closely in patients with eGFR 30-60
  - Discontinue if acute kidney injury occurs
- **Source:** FDA Prescribing Information; Drugs.com Disease Interactions

### 2. Volume Depletion/Hypotension (Major)
- **At-Risk Patients:**
  - Elderly (≥65 years)
  - Patients on diuretics
  - Patients with low systolic blood pressure
  - Patients with eGFR <60 mL/min/1.73m²
- **Risk:** Symptomatic hypotension, falls, acute kidney injury
- **Management:**
  - Assess and correct volume depletion before starting
  - Consider reducing diuretic dose
  - Monitor blood pressure
  - Encourage adequate hydration
- **Source:** FDA Prescribing Information

### 3. Diabetic Ketoacidosis Risk (Major)
- **Concern:** SGLT2 inhibitors increase ketoacidosis risk, including euglycemic DKA
- **Risk Factors:**
  - Acute illness
  - Reduced food/fluid intake
  - Reduced insulin doses
  - Surgery
  - Excessive alcohol
- **Management:**
  - Withhold Jardiance during acute illness
  - Stop 3-4 days before scheduled surgery
  - Educate patients on DKA symptoms (nausea, vomiting, abdominal pain, fatigue)
  - Check ketones if symptoms develop
- **Source:** FDA Prescribing Information; FDA Safety Communication

### 4. Genital Mycotic Infections (Moderate)
- **Risk:** Increased due to glucosuria creating favorable environment for yeast
- **Affected Patients:** More common in females and uncircumcised males
- **Management:** 
  - Patient education on signs/symptoms
  - Treat with antifungal therapy as needed
  - Good hygiene practices
- **Source:** FDA Prescribing Information

### 5. Urinary Tract Infections (Moderate)
- **Risk:** Glucosuria may increase UTI risk
- **Serious Concern:** Urosepsis and pyelonephritis reported
- **Management:**
  - Monitor for UTI symptoms
  - Prompt treatment if UTI develops
  - Consider discontinuation for recurrent infections
- **Source:** FDA Prescribing Information

### 6. Necrotizing Fasciitis of Perineum (Fournier's Gangrene) (Rare but Serious)
- **Risk:** Rare, life-threatening bacterial infection
- **Symptoms:** Fever, malaise, tenderness/redness/swelling of genitals extending to perineum
- **Management:** 
  - Urgent surgical intervention required
  - Discontinue Jardiance immediately if suspected
  - Patient education on warning signs
- **Source:** FDA Safety Communication; Prescribing Information

---

## Summary Statistics
- **Total Known Drug Interactions:** 443
- **Major Interactions:** 3
- **Moderate Interactions:** 431
- **Minor Interactions:** 9
- **Disease Interactions:** 3 (renal dysfunction, DKA, volume depletion)
- **Food/Alcohol Interactions:** 1

---

## Clinical Recommendations for Safe Use

1. **Before Starting Jardiance:**
   - Assess renal function (eGFR)
   - Evaluate volume status and blood pressure
   - Review medication list for diuretics, insulin, sulfonylureas
   - Assess risk factors for DKA
   - Consider history of genital/urinary infections

2. **Dosing:**
   - Type 2 Diabetes: Start 10 mg daily; may increase to 25 mg
   - Heart Failure: 10 mg daily
   - CKD: 10 mg daily
   - Take in the morning with or without food

3. **Monitoring:**
   - Renal function periodically
   - Blood pressure, especially at initiation
   - Blood glucose (especially with insulin/sulfonylureas)
   - Signs of volume depletion
   - Signs of genital/urinary infections

4. **Dose Adjustments with Interacting Drugs:**
   - REDUCE insulin dose when adding Jardiance
   - REDUCE sulfonylurea dose when adding Jardiance
   - May need to REDUCE diuretic dose

5. **When to Hold Jardiance:**
   - Before surgery (3-4 days prior)
   - During acute illness with reduced food/fluid intake
   - If DKA symptoms develop
   - If severe UTI or genital infection occurs

6. **Patient Education:**
   - Stay hydrated
   - Recognize symptoms of hypoglycemia (if on insulin/sulfonylureas)
   - Recognize symptoms of DKA
   - Signs of genital yeast infections and UTIs
   - Report any perineal pain/tenderness urgently

---

## References
1. FDA Prescribing Information - Jardiance (Empagliflozin)
2. Drugs.com Drug Interactions Database (https://www.drugs.com/drug-interactions/empagliflozin,jardiance.html)
3. GoodRx - What Drugs Should Not Be Taken with Jardiance
4. Medscape Drug Interactions Reference
5. WebMD - Jardiance Interactions
6. RxList - Jardiance Drug Information
7. FDA Drug Safety Communication - SGLT2 Inhibitors
8. American Diabetes Association Standards of Care
9. EMPEROR and EMPA-REG OUTCOME Clinical Trial Data
